Oncology:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      UK-VNCCLL-230003. Date of Preparation: March 2023.

      FRONTIERS promotional meetings are fully funded and organised by AbbVie.

      On demand: Access content from previous meetings

      9th – 10th September 2022

      FRONTIERS was a two-day, CPD accredited, in-person meeting in London. The meeting brought together a UK and international faculty of AML and CLL thought leaders to review emerging data, explore practical management and learn about new approaches to service design.

      We invite you to view key presentations from the FRONTIERS meeting. 

      Othman Al-Sawaf   

      2022 CLL data updates 

      Dr Dima El-Sharkawi 

      CLL: Treatment guidelines and practical management      

      Toby Eyre  

      Seeking paradigms in CLL management – retreatment and treatment sequencing          

      Nicolas Martinez-Calle  

      CLL - Best practice approach to on-boarding patients with venetoclax          

      Paul Moss

      Living with COVID - what we've learned and how COVID continues to impact CLL and AML patient care          

      8th November 2021

      Dr Talha Munir 

      Points of Practice – practical management advice when treating with venetoclax         

      Contact us to join us for future events

      VENCLYXTO PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected]

      UK-VNCCLL-230052. Date of preparation: February 2023.